SDC1 and congenital rubella syndrome: In this context, the ADC BT062 led to skin and mucosal toxicities, the radioimmunoconjugate B-B4-I131 caused severe side effects in one patient after treatment, and CRS and neurotoxicity mediated by proinflammatory cytokines upon CAR-T cell activation represent another issue to be addressed, although no significant toxicities were observed in a small pilot study with CD138 CAR-T cells (206, 207).